ArticleCells2026
Lack of Oxygen and/or Glucose Differentially Potentiates Aβ40
Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
Abstract
Cerebrovascular damage/dysfunction promote cerebral hypoperfusion early within Alzheimer's Disease (AD). Cerebral hypoperfusion is also a common consequence of cardiovascular risk factors/diseases, typically manifesting in midlife when AD pathology initiates, and contributing to AD onset/progression. We demonstrated that AβQ22 (vasculotropic Dutch mutant) and Aβ42 promote cerebral endothelial cell (cEC) apoptosis, barrier permeability, and angiogenic impairments. Prior research indicates hypoperfusion promotes analogous EC dysfunction. Aβ accumulates within a hypoperfused environment in AD, but whether Aβ exposure of cECs under hypoperfusion potentiates dysfunction through activation of shared molecular mechanisms remains unknown. We treated cECs with Aβ40-Q22/Aβ42, glucose deprivation (GD), or both under normoxia or hypoxia. Cell death, barrier dysfunction/permeability, proinflammatory activation, and angiogenesis impairment were evaluated. Overall, GD and/or hypoxia potentiated Aβ-induced cEC death, barrier dysfunction, inflammatory activation, and angiogenesis/wound healing failure. Hypoperfusion specifically exacerbated AβQ22-mediated cEC apoptosis, TEER/ZO1 decreases, ICAM1/IL6/IL8 upregulation, monocyte migration, and wound healing impairments. Differentially, hypoperfusion strongly potentiated Aβ42-mediated necrosis and MMP2/pClaudin-5/IFNγ/IL12p70 increases. GD exerted stronger increases in caspase-3 activation/apoptosis and MMP2/ICAM1 expression, while hypoxia increased necrosis and ZO1/pro-angiogenic proteins. This study reveals specific, selective mechanisms that hypoxia/GD and amyloidosis mutually activate to produce cEC dysfunction, highlighting new molecular targets against vascular pathology in AD/CAA comorbid with hypoperfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.